Cancer Research

 
Stock Quotes for Cancer Research top ^
  • Industry: Health Information Services
  • Sector: Technology
  • Stock Type: Distressed
Sign-up for cthz investment picks

 
News Articles for Cancer Research top ^
Employees to hold fundraisers at more than 100 airports in addition to jet aircraft drag competition ATLANTA , May 1, 2014 /PRNewswire/ -- Delta Air Lines (NYSE: DAL) will hold more than 100 fundraising events next week as part of its partnership with the American Cancer Society with a new goal to generate $1.3 million to support research and other endeavors to end cancer.
Sign-up for Delta Air Lines Partners with American Cancer Society to Achieve $1.3 million in Fundraising to End Cancer investment picks
The Mantle-Cell and Follicular Lymphoma Tests Were Validated In Research Collaborations With Memorial Sloan Kettering and Have Been Successfully Licensed Under Both CLIA and New York State Regulations Tests Address Over One-Third of non-Hodgkin Lymphomas And Will Be Made Available As Part of Comprehensive Testing Programs To Provide Targeted Diagnostic And Prognostic Information RUTHERFORD, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, today announced it has received CLIA and New York state approvals for clinical use of its proprietary mature B-cell neoplasm array, or MatBA ® for Follicular Lymphoma (MatBA ® -FL) and Mantle-Cell Lymphoma (MatBA ® -MCL). Both tests further extend the portfolio in hematologic cancers being developed by CGI and both were developed and validated via a research collaboration with Memorial Sloan-Kettering Cancer Center.
Sign-up for Cancer Genetics Launches Genomic Tests for Follicular Lymphoma and Mantle Cell Lymphoma - Further Extends Unique Position in Targeted Testing of Hematologic Cancers investment picks
2014/5/4
Alliance of Australian and U.S. researchers and children's cancer advocates focused on developing drugs as potential treatments for neuroblastoma, the most common solid form of childhood cancer SYDNEY and COLUMBUS, Ohio , May 4, 2014 /PRNewswire/ -- Researchers and children's cancer advocates in Australia and the U.S. have formed a unique research and development alliance to facilitate development of treatments for children fighting neuroblastoma, the most common and fatal form of solid cancer affecting infants.
Sign-up for Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood Cancers investment picks
BEIJING , May 16, 2014 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM) , a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China , today announced it has engaged The University of Texas MD Anderson Cancer Center ("MD Anderson") as a consultant for its cancer hospital projects under planning in Shanghai and Beijing .
Sign-up for Concord Medical Signs Consulting Agreement with MD Anderson Cancer Center investment picks
LOS ANGELES, April 21, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX) , a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced execution of an exclusive commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University (OHSU) for a proprietary next generation sequencing panel for lung cancer.
Sign-up for Response Genetics Enters Next Generation Sequencing Market With Proprietary Panel for Lung Cancer Developed by the Knight Cancer Institute at Oregon Health & Science University investment picks
REDWOOD CITY, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration (FDA) Department of Orphan Products Development has granted orphan drug designation to demcizumab (anti-DLL4, OMP-21M18) for the treatment of pancreatic cancer.
Sign-up for OncoMed Receives Orphan Drug Designation From the FDA for Demcizumab in Pancreatic Cancer investment picks
PRINCETON, N.J., May 1, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq:ADXS) , a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.
Sign-up for Advaxis Receives Orphan Drug Designation for Treatment of Invasive Cervical Cancer investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1114892&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation to Sponsor the 2014 Cancer Cachexia Conference investment picks
PRINCETON, N.J., April 14, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology.
Sign-up for Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology investment picks
2014/4/28
Annual cross-state run has raised more than $1.4 million over 16 years ATLANTA , April 28, 2014 /PRNewswire/ -- Georgia Power employees are continuing the fight to end cancer by running from St.
Sign-up for Georgia Power Employees Run 400 Miles In Two And A Half Days To Fight Cancer investment picks
2014/5/1
MM-398 in combination with 5-fluorouracil and leucovorin demonstrates statistically significant advantage compared to control arm Plan to submit New Drug Application in 2014 Conference Call Scheduled for 8:30 a.m. ET Today CAMBRIDGE, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone.
Sign-up for Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer investment picks
SAN DIEGO , May 5, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP) , an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin ® (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers.
Sign-up for MEI Pharma Initiates Clinical Study Of Mitochondrial Inhibitor Drug Candidate ME-344 In Small Cell Lung And Ovarian Cancers investment picks
RUTHERFORD, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, today announced that an overview of the Company's business and commercial strategy will be given by CGI's Chief Executive Officer, Panna Sharma, at the UBS Global Healthcare Conference, being held at the Sheraton New York Times Square from May 19-21.
Sign-up for Cancer Genetics, Inc. to Present at the UBS Global Healthcare Conference investment picks
PRINCETON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing cancer immunotherapies, announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma.
Sign-up for Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer investment picks
BOSTON, May 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings.
Sign-up for ZIOPHARM Announces Oral Presentation Highlighting Ad-RTS-IL-12 Results Correlated With Reducing Cancer Stem Cells in the Brain at ASGCT 17th Annual Meeting investment picks
SALT LAKE CITY, May 6, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed a three-year contract with UnitedHealthcare.
Sign-up for Myriad and UnitedHealthcare Sign Three-Year Agreement Making myRisk(TM) Hereditary Cancer Test Available to United Members investment picks
ELMWOOD PARK, N.J., April 16, 2014 (GLOBE NEWSWIRE) -- Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announced today that it has hired Robert Daber, Ph.D. to assume the dual role as Director of Research and Development and Director of Cancer Genetics at its Elmwood Park international headquarters.
Sign-up for Bio-Reference Laboratories, Inc. Announces That Robert Daber, Ph.D. Will Join Company as Director of R&D and Cancer Genetics investment picks
HASBROUCK HEIGHTS, N.J., May 6, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer.
Sign-up for Nymox Announces Positive New Prostate Cancer Clinical Trial Results investment picks
SALT LAKE CITY, May 20, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association (AUA) Annual Meeting in Orlando, Fla.
Sign-up for Prolaris(R) Test Predicts Mortality Risk in Prostate Cancer Biopsy Study investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Cancer Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Canadian Utilities  |  Next: Cap Balanced Fund